

Shingo Nakayamada

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3453479/publications.pdf>

Version: 2024-02-01

121
papers

3,930
citations

147726

31
h-index

143943

57
g-index

128
all docs

128
docs citations

128
times ranked

6098
citing authors

#	ARTICLE	IF	CITATIONS
1	Early Th1 Cell Differentiation Is Marked by a Tfh Cell-like Transition. <i>Immunity</i> , 2011, 35, 919-931.	6.6	364
2	STATs Shape the Active Enhancer Landscape of T Cell Populations. <i>Cell</i> , 2012, 151, 981-993.	13.5	325
3	Helper T cell diversity and plasticity. <i>Current Opinion in Immunology</i> , 2012, 24, 297-302.	2.4	267
4	Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. <i>Nature Reviews Rheumatology</i> , 2022, 18, 133-145.	3.5	193
5	Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 389-395.	0.5	149
6	Janus kinases to jakinibs: from basic insights to clinical practice. <i>Rheumatology</i> , 2019, 58, i4-i16.	0.9	111
7	Type I IFN Induces Binding of STAT1 to Bcl6: Divergent Roles of STAT Family Transcription Factors in the T Follicular Helper Cell Genetic Program. <i>Journal of Immunology</i> , 2014, 192, 2156-2166.	0.4	95
8	Precision medicine using different biological DMARDs based on characteristic phenotypes of peripheral T helper cells in psoriatic arthritis. <i>Rheumatology</i> , 2019, 58, 336-344.	0.9	92
9	Janus Kinase Inhibitor Baricitinib Modulates Human Innate and Adaptive Immune System. <i>Frontiers in Immunology</i> , 2018, 9, 1510.	2.2	89
10	Peripheral Immunophenotyping Identifies Three Subgroups Based on T Cell Heterogeneity in Lupus Patients. <i>Arthritis and Rheumatology</i> , 2017, 69, 2029-2037.	2.9	74
11	Metabolic Reprogramming Commits Differentiation of Human CD27+IgD+ B Cells to Plasmablasts or CD27 ^{hi} IgD ^{hi} Cells. <i>Journal of Immunology</i> , 2017, 199, 425-434.	0.4	72
12	Differential effects of biological DMARDs on peripheral immune cell phenotypes in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2018, 57, 164-174.	0.9	70
13	Î21 Integrin/Focal Adhesion Kinase-mediated Signaling Induces Intercellular Adhesion Molecule 1 and Receptor Activator of Nuclear Factor ÎB Ligand on Osteoblasts and Osteoclast Maturation. <i>Journal of Biological Chemistry</i> , 2003, 278, 45368-45374.	1.6	68
14	Up-Regulation of TLR7-Mediated IFN-Î± Production by Plasmacytoid Dendritic Cells in Patients With Systemic Lupus Erythematosus. <i>Frontiers in Immunology</i> , 2018, 9, 1957.	2.2	66
15	Hydroxychloroquine efficiently suppresses inflammatory responses of human class-switched memory B cells via Toll-like receptor 9 inhibition. <i>Clinical Immunology</i> , 2018, 195, 1-7.	1.4	66
16	IL-6 and sIL-6R induces STAT3-dependent differentiation of human VSMCs into osteoblast-like cells through JMJD2B-mediated histone demethylation of RUNX2. <i>Bone</i> , 2019, 124, 53-61.	1.4	65
17	Expansion of T follicular helper-T helper 1 like cells through epigenetic regulation by signal transducer and activator of transcription factors. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1354-1361.	0.5	62
18	Th22 Cells Promote Osteoclast Differentiation via Production of IL-22 in Rheumatoid Arthritis. <i>Frontiers in Immunology</i> , 2018, 9, 2901.	2.2	58

#	ARTICLE	IF	CITATIONS
19	Induction of Regulatory T Cells and Its Regulation with Insulin-like Growth Factor/Insulin-like Growth Factor Binding Protein-4 by Human Mesenchymal Stem Cells. <i>Journal of Immunology</i> , 2017, 199, 1616-1625.	0.4	53
20	Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis. <i>BioDrugs</i> , 2016, 30, 407-419.	2.2	52
21	Genetic determinants and an epistasis of <i>LILRA3</i> and HLA-B*52 in Takayasu arteritis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 13045-13050.	3.3	51
22	Conversion of T Follicular Helper Cells to T Follicular Regulatory Cells by Interleukin-2 Through Transcriptional Regulation in Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2021, 73, 132-142.	2.9	48
23	Rapid Enhancer Remodeling and Transcription Factor Repurposing Enable High Magnitude Gene Induction upon Acute Activation of NK Cells. <i>Immunity</i> , 2020, 53, 745-758.e4.	6.6	46
24	Spontaneous Differentiation of Human Mesenchymal Stem Cells on Poly-Lactic-Co-Glycolic Acid Nano-Fiber Scaffold. <i>PLoS ONE</i> , 2016, 11, e0153231.	1.1	46
25	Spatial congregation of STAT binding directs selective nuclear architecture during T-cell functional differentiation. <i>Genome Research</i> , 2013, 23, 462-472.	2.4	44
26	Discontinuation of infliximab in rheumatoid arthritis patients in clinical remission. <i>Modern Rheumatology</i> , 2008, 18, 460-464.	0.9	42
27	BAFF- and APRIL-targeted therapy in systemic autoimmune diseases. <i>Inflammation and Regeneration</i> , 2016, 36, 6.	1.5	42
28	Comparison of the efficacies of abatacept and tocilizumab in patients with rheumatoid arthritis by propensity score matching. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1321-1327.	0.5	42
29	Amplification of IL-21 signalling pathway through Bruton's tyrosine kinase in human B cell activation. <i>Rheumatology</i> , 2015, 54, 1488-1497.	0.9	41
30	Relevance of interferon-gamma in pathogenesis of life-threatening rapidly progressive interstitial lung disease in patients with dermatomyositis. <i>Arthritis Research and Therapy</i> , 2018, 20, 240.	1.6	39
31	Tofacitinib, a JAK inhibitor, inhibits human B cell activation in vitro. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 2213-2215.	0.5	38
32	Efficacy and safety of mizoribine for the treatment of Sjögren's syndrome: a multicenter open-label clinical trial. <i>Modern Rheumatology</i> , 2007, 17, 464-469.	0.9	33
33	Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1130-1136.	0.5	33
34	A twin study of rheumatoid arthritis in the Japanese population. <i>Modern Rheumatology</i> , 2016, 26, 685-689.	0.9	32
35	B cell phenotypes, signaling and their roles in secretion of antibodies in systemic lupus erythematosus. <i>Clinical Immunology</i> , 2018, 186, 21-25.	1.4	32
36	Use of mesenchymal stem cells seeded on the scaffold in articular cartilage repair. <i>Inflammation and Regeneration</i> , 2018, 38, 4.	1.5	32

#	ARTICLE	IF	CITATIONS
37	Baricitinib for the treatment of rheumatoid arthritis and systemic lupus erythematosus: a 2019 update. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 693-700.	1.3	31
38	Baricitinib for the treatment of rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 911-919.	1.3	29
39	Etidronate prevents high dose glucocorticoid induced bone loss in premenopausal individuals with systemic autoimmune diseases. <i>Journal of Rheumatology</i> , 2004, 31, 163-6.	1.0	28
40	Glycolaldehyde-modified advanced glycation end-products inhibit differentiation of human monocytes into osteoclasts via upregulation of IL-10. <i>Bone</i> , 2019, 128, 115034.	1.4	26
41	Activation signal transduction by α 21 integrin in T cells from patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2007, 56, 1559-1568.	6.7	25
42	Efficacy and safety of mizoribine for the treatment of Sjögren's syndrome: a multicenter open-label clinical trial. <i>Modern Rheumatology</i> , 2007, 17, 464-469.	0.9	24
43	IgG4-related Pleuritis with Elevated Adenosine Deaminase in Pleural Effusion. <i>Internal Medicine</i> , 2018, 57, 2251-2257.	0.3	23
44	Chemical JAK inhibitors for the treatment of rheumatoid arthritis. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 2215-2225.	0.9	22
45	Enlarged perivascular spaces are associated with the disease activity in systemic lupus erythematosus. <i>Scientific Reports</i> , 2017, 7, 12566.	1.6	22
46	Effectiveness and safety of mepolizumab in combination with corticosteroids in patients with eosinophilic granulomatosis with polyangiitis. <i>Arthritis Research and Therapy</i> , 2021, 23, 86.	1.6	22
47	Usefulness of initial histological features for stratifying Sjogren's syndrome responders to mizoribine therapy. <i>Rheumatology</i> , 2009, 48, 1279-1282.	0.9	20
48	Etanercept overcomes P-glycoprotein-induced drug resistance in lymphocytes of patients with intractable rheumatoid arthritis. <i>Modern Rheumatology</i> , 2010, 20, 139-146.	0.9	20
49	In vitro pharmacological effects of peficitinib on lymphocyte activation: a potential treatment for systemic sclerosis with JAK inhibitors. <i>Rheumatology</i> , 2020, 59, 1957-1968.	0.9	20
50	Relevance of lymphocyte subsets to B cell-targeted therapy in systemic lupus erythematosus. <i>International Journal of Rheumatic Diseases</i> , 2015, 18, 208-218.	0.9	19
51	Human dendritic cell-derived osteoclasts with high bone resorption capacity and T cell stimulation ability. <i>Bone</i> , 2021, 142, 115616.	1.4	19
52	An enhanced mitochondrial function through glutamine metabolism in plasmablast differentiation in systemic lupus erythematosus. <i>Rheumatology</i> , 2022, 61, 3049-3059.	0.9	19
53	Lymphocyte phenotype and its application to precision medicine in systemic autoimmune diseases. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 1146-1150.	1.6	18
54	Anti-PD-1 Antibody Therapy Induces Hashimoto's Disease with an Increase in Peripheral Blood Follicular Helper T Cells. <i>Thyroid</i> , 2017, 27, 1335-1336.	2.4	17

#	ARTICLE	IF	CITATIONS
55	Effectiveness and safety of hydroxychloroquine therapy with or without corticosteroid in patients with systemic lupus erythematosus. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 434-442.	0.9	17
56	Immunophenotype involved in IgG4-related disease. <i>Modern Rheumatology</i> , 2019, 29, 226-230.	0.9	17
57	Differentiation, functions, and roles of T follicular regulatory cells in autoimmune diseases. <i>Inflammation and Regeneration</i> , 2021, 41, 14.	1.5	17
58	Small GTP-binding protein Rho-mediated signaling promotes proliferation of rheumatoid synovial fibroblasts. <i>Arthritis Research</i> , 2005, 7, R476.	2.0	16
59	Histamine inhibits differentiation of skin fibroblasts into myofibroblasts. <i>Biochemical and Biophysical Research Communications</i> , 2015, 463, 434-439.	1.0	16
60	Quantitative susceptibility mapping in patients with systemic lupus erythematosus: detection of abnormalities in normal-appearing basal ganglia. <i>European Radiology</i> , 2016, 26, 1056-1063.	2.3	16
61	Evaluation of the alternative classification criteria of systemic lupus erythematosus established by Systemic Lupus International Collaborating Clinics (SLICC). <i>Modern Rheumatology</i> , 2018, 28, 642-648.	0.9	16
62	Tumour necrosis factor alpha promotes secretion of 14-3-3 σ by inducing necroptosis in macrophages. <i>Arthritis Research and Therapy</i> , 2020, 22, 24.	1.6	16
63	Multi-Source Pathways of T Follicular Helper Cell Differentiation. <i>Frontiers in Immunology</i> , 2021, 12, 621105.	2.2	16
64	Abatacept therapy reduces CD28+CXCR5+ follicular helper-like T cells in patients with rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 562-570.	0.4	16
65	Overcoming treatment unresponsiveness mediated by P-glycoprotein overexpression on lymphocytes in refractory active systemic lupus erythematosus. <i>Modern Rheumatology</i> , 2005, 15, 28-32.	0.9	15
66	Interleukin-23 drives expansion of Thelper 17 cells through epigenetic regulation by signal transducer and activators of transcription 3 in lupus patients. <i>Rheumatology</i> , 2020, 59, 3058-3069.	0.9	15
67	Safety and efficacy of fostamatinib in rheumatoid arthritis patients with an inadequate response to methotrexate in phase II OSKIRA-ASIA-1 and OSKIRA-ASIA-1X study. <i>Rheumatology</i> , 2021, 60, 2884-2895.	0.9	14
68	Prophylaxis against pneumocystis pneumonia in rheumatoid arthritis patients treated with b/tsDMARDs: insights from 3787 cases in the FIRST registry. <i>Rheumatology</i> , 2022, 61, 1831-1840.	0.9	14
69	Comparative study of corticosteroid monotherapy, and TNF inhibitors with or without corticosteroid in patients with refractory entero-Behçetâ€™s disease. <i>Arthritis Research and Therapy</i> , 2019, 21, 151.	1.6	13
70	Correlation between serological biomarkers of extracellular matrix turnover and lung fibrosis and pulmonary artery hypertension in patients with systemic sclerosis. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 532-539.	0.9	13
71	Efficacy of mizoribine treatment in patients with Sjögrenâ€™s syndrome: an open pilot trial. <i>Modern Rheumatology</i> , 2003, 13, 339-345.	0.9	12
72	Comparison of efficacy of TNF inhibitors and abatacept in patients with rheumatoid arthritis; Adjusted with propensity score matching. <i>Clinical Immunology</i> , 2018, 191, 67-74.	1.4	12

#	ARTICLE	IF	CITATIONS
73	Critical roles of super-enhancers in the pathogenesis of autoimmune diseases. <i>Inflammation and Regeneration</i> , 2020, 40, 16.	1.5	12
74	Enhanced Fatty Acid Synthesis Leads to Subset Imbalance and IFN- β Overproduction in T Helper 1 Cells. <i>Frontiers in Immunology</i> , 2020, 11, 593103.	2.2	12
75	Involvement of lncRNA IL21-AS1 in interleukin-2 and T follicular regulatory cell activation in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2021, 23, 302.	1.6	12
76	Type I and II interferons commit to abnormal expression of chemokine receptor on B cells in patients with systemic lupus erythematosus. <i>Clinical Immunology</i> , 2019, 200, 1-9.	1.4	11
77	A case of life-threatening refractory polychondritis successfully treated with combined intensive immunosuppressive therapy with methotrexate. <i>Modern Rheumatology</i> , 2007, 17, 144-147.	0.9	10
78	Favorable efficacy of rituximab in ANCA-associated vasculitis patients with excessive B cell differentiation. <i>Arthritis Research and Therapy</i> , 2020, 22, 141.	1.6	10
79	The additive effects of hydroxychloroquine to maintenance therapy with standard of care in patients with systemic lupus erythematosus. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 549-558.	0.9	10
80	Efficacy and safety of belimumab during maintenance therapy in patients with systemic lupus erythematosus. <i>Rheumatology</i> , 2022, 61, 3614-3626.	0.9	10
81	Clinical relevance of T follicular helper cells in systemic lupus erythematosus. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 1143-1150.	1.3	9
82	Clinical aspects in patients with rheumatoid arthritis complicated with lymphoproliferative disorders without regression after methotrexate withdrawal and treatment for arthritis after regression of lymphoproliferative disorders. <i>Modern Rheumatology</i> , 2021, 31, 94-100.	0.9	8
83	Pathological role of activated mTOR in CXCR3+ memory B cells of rheumatoid arthritis. <i>Rheumatology</i> , 2021, 60, 5452-5462.	0.9	7
84	A patient with eosinophilic granulomatosis with polyangiitis successfully weaned from corticosteroids through remission induction therapy with mepolizumab. <i>Modern Rheumatology Case Reports</i> , 2022, 6, 243-247.	0.3	7
85	Serum TNF α levels at 24 h after certolizumab pegol predict effectiveness at week 12 in patients with rheumatoid arthritis from TSUBAME study. <i>Arthritis Research and Therapy</i> , 2021, 23, 154.	1.6	6
86	Rituximab in the real-world treatment of lupus nephritis: A retrospective cohort study in Japan. <i>Modern Rheumatology</i> , 2023, 33, 145-153.	0.9	6
87	Human urinary trypsin inhibitor bolus infusion improved severe interstitial pneumonia in mixed connective tissue disease. <i>Modern Rheumatology</i> , 2005, 15, 374-380.	0.9	5
88	Mediastinal and axillar lymphadenopathy in patients with rheumatoid arthritis: prevalence and clinical significance. <i>Clinical Imaging</i> , 2019, 55, 140-143.	0.8	5
89	5-year remission rate after the discontinuation of adalimumab in patients with rheumatoid arthritis: Long-term follow-up results of the HONOR study. <i>Modern Rheumatology</i> , 2020, 30, 799-806.	0.9	5
90	Pancreas-protective effect of rituximab for acute-onset type 1 diabetes in the honeymoon period: a case report. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2016, 2016, 160020.	0.2	5

#	ARTICLE	IF	CITATIONS
91	Pathological relevance and treatment perspective of JAK targeting in systemic lupus erythematosus. Expert Review of Clinical Immunology, 2022, , .	1.3	5
92	Eosinophilic granulomatosis with polyangiitis exhibits T cell activation and IgG4 immune response in the tissue; comparison with IgG4-related disease. RMD Open, 2022, 8, e002086.	1.8	5
93	Nailfold microvascular abnormalities are associated with a higher prevalence of pulmonary arterial hypertension in patients with MCTD. Rheumatology, 2022, 61, 4875-4884.	0.9	5
94	Impact of serum interleukin-22 as a biomarker for the differential use of molecular targeted drugs in psoriatic arthritis: a retrospective study. Arthritis Research and Therapy, 2022, 24, 86.	1.6	5
95	Regulatory Mechanism of The Induction of Regulatory T Cells through Growth Factors Released by Human Mesenchymal Stem Cells. Critical Reviews in Immunology, 2018, 38, 471-478.	1.0	4
96	An Autopsy Case with Cerebral Hemorrhaging due to disseminated Aspergillosis During Glucocorticoid Therapy for Overlap Syndrome of Systemic Lupus Erythematosus and Systemic Sclerosis. Internal Medicine, 2019, 58, 1023-1027.	0.3	4
97	mTOR activation in CD8+ cells contributes to disease activity of rheumatoid arthritis and increases therapeutic response to TNF inhibitors. Rheumatology, 2021, , .	0.9	4
98	Clinical, radiographic and functional efficacy of abatacept in routine care for rheumatoid arthritis patients: Abatacept Leading Trial for RA on Imaging Remission (ALTAIR) study. Clinical and Experimental Rheumatology, 2016, 34, 834-841.	0.4	4
99	Optimal Biologic Selection for Treatment of Psoriatic Arthritis: the Approach to Precision Medicine. Current Rheumatology Reports, 2019, 21, 21.	2.1	3
100	Selection of treatment regimens based on shared decision-making in patients with rheumatoid arthritis on remission in the FREE-J study. Rheumatology, 2022, 61, 4273-4285.	0.9	3
101	Soluble IL-6R promotes chondrogenic differentiation of mesenchymal stem cells to enhance the repair of articular cartilage defects using a rat model for rheumatoid arthritis. Clinical and Experimental Rheumatology, 2020, 38, 670-679.	0.4	3
102	Short-Term Prognostic Factors in Hospitalized Herpes Zoster Patients and Its Associated Cerebro-Cardiovascular Events: A Nationwide Retrospective Cohort in Japan. Frontiers in Medicine, 2022, 9, 843809.	1.2	3
103	The two cases of acute acalculous cholecystitis associated with systemic lupus erythematosus (SLE) presented different clinical aspects. Modern Rheumatology Case Reports, 2019, 3, 114-118.	0.3	2
104	A case of bone destruction caused by chronic non-bacterial osteomyelitis (CNO) successfully repaired with a tumour necrosis factor- α (TNF- α) inhibitor, adalimumab. Modern Rheumatology Case Reports, 2020, 4, 196-201.	0.3	2
105	A case of eosinophilic granulomatosis with polyangiitis as a mimicker of IgG4-related disease. Modern Rheumatology Case Reports, 2020, 4, 278-282.	0.3	2
106	Down-regulated Th17 cells in a patient with familial Mediterranean fever associated with amyloid A amyloidosis in the treatment of canakinumab. Modern Rheumatology Case Reports, 2022, , .	0.3	2
107	Efficacy of mizoribine treatment in patients with Sjögren's syndrome: an open pilot trial. Modern Rheumatology, 2003, 13, 339-345.	0.9	2
108	The occurrence of hypertrophic pachymeningitis with infiltration of IgG4-positive plasma cells and with different aetiology: report of three cases. Modern Rheumatology Case Reports, 2017, 1, 108-112.	0.3	1

#	ARTICLE	IF	CITATIONS
109	A case of systemic lupus erythematosus in which Cushing's syndrome caused by adrenal adenoma accidentally occurred during long-term maintenance therapy with corticosteroids. <i>Modern Rheumatology Case Reports</i> , 2020, 4, 34-38.	0.3	1
110	Intercellular adhesion molecule-1 (ICAM-1) mediated gene delivery to rheumatoid synovial cells using the Fab fragments of anti-ICAM-1 monoclonal antibody. <i>Japanese Journal of Clinical Immunology</i> , 2000, 23, 533-537.	0.0	1
111	T helper cells expressing fractalkine receptor and bearing T follicular helper 1-like cell functions in patients with IgG4-related disease. <i>Rheumatology</i> , 2021, , .	0.9	1
112	Efficacy and safety of high-dose of mycophenolate mofetil compared with cyclophosphamide pulse therapy as induction therapy in Japanese patients with proliferative lupus nephritis. <i>Modern Rheumatology</i> , 2022, 32, 1077-1085.	0.9	1
113	Successful treatment with etanercept in a case of seronegative rheumatoid arthritis with corticosteroid/methotrexate-resistant pemphigus erythematosus. <i>Modern Rheumatology Case Reports</i> , 2018, 2, 137-142.	0.3	0
114	THU0243's ROLE OF METHIONINE AND ITS TRANSPORTER CD98 IN HUMAN B CELL DIFFERENTIATION AND THE RELEVANCE TO PATHOLOGICAL PROCESSES OF SLE. , 2019, , .		0
115	SAT0026's IMPACT OF TOCILIZUMAB ON IMMUNE PHENOTYPES IN PATIENTS WITH LARGE VESSEL VASCULITIS. , 2019, , .		0
116	FRI0177's THE ADDITIVE EFFECTS OF HYDROXYCHLOROQUINE TO MAINTENANCE THERAPY WITH STANDARD OF CARE IN PATIENTS WITH SYSTEMIC LUPUS: ERYTHEMATOSUS. , 2019, , .		0
117	SAT0008's IL-23 DRIVES PATHOGENIC TH17 CELLS THROUGH EPIGENETIC REGULATION BY STAT3 IN SLE PATIENTS. , 2019, , .		0
118	FRI0246's CELLULAR/FIBROCELLULAR CRESCENT IS A 52-WEEK AND LONG-TERM POOR PROGNOSTIC FACTOR OF ACTIVE LUPUS NEPHRITIS. , 2019, , .		0
119	THU0057B's TNF-ALPHA INDUCES NECROPTOSIS-LIKE DEATH OF MACROPHAGES AND PROMOTES EXTRACELLULAR RELEASE OF 14's 3. , 2019, , .		0
120	Fulminant Type 1 Diabetes with Diversity in Peripheral Blood Lymphocytes: A Case Report. <i>Journal of UOEH</i> , 2020, 42, 57-62.	0.3	0
121	Discovery of a novel IgG ² and Fcγ ³ RIIB cross-linking antibody, ASP2713, and its potential application in the treatment of systemic lupus erythematosus. <i>International Immunopharmacology</i> , 2021, 101, 108343.	1.7	0